THE THERAPEUTIC POTENTIAL OF IVERMECTIN FOR COVID-19: A SYSTEMATIC REVIEW OF MECHANISMS AND EVIDENCE

Stefanie Kalfas, MD¹

Kumar Visvanathan, MBBS FRACP PhD^{2,3}

Kim Chan, DSc PhD⁴

John Drago, MBBS FRACP PhD^{1,5*}

¹Florey Institute of Neuroscience and Mental Health, University of Melbourne, VIC, Australia

²Department of infectious Diseases, St. Vincent's Hospital, Melbourne, VIC, Australia

³Department of Medicine, Dentistry and Health Sciences, University of Melbourne, VIC, Australia

⁴Sydney Pharmacy School, Faculty of Medicine and Health, University of Sydney, NSW, Australia

⁵Department of Neurology, St. Vincent's Hospital, Melbourne, VIC, Australia

*corresponding author: john.drago@florey.edu.au

Word count (excluding abstract): 3,676

53 ABSTRACT

54 Introduction: Ivermectin is a commonly used antihelminthic agent with over 35 years of
55 established safety data in humans. Recent data demonstrates antiviral activity in vitro
56 against SARS-CoV-2, in addition to a range of viruses. In vitro and animal models also provide
57 evidence of immunomodulatory action. These additional modes of action are supported by
58 in silico modelling, which propose a number of viral and host targets that would mediate
59 these effects.

60 Objectives: The aim of this study is to systematically review the published and preprint
61 clinical literature and study results that assessed the potential role of ivermectin as a COVID-
62 19 therapeutic and prophylactic agent.

63 Methods: We conducted a comprehensive review of PubMed, medRxiv, ClinicalTrials.gov,
64 Global Coronavirus COVID-19 Clinical Trial Tracker, World Health Organization International
65 Clinical Trials Registry Platform, EU Clinical Trials Register, ANZ clinical trials registry, and
66 references from relevant articles.

67 Results: Search keywords- "COVID-19 (and synonyms) AND ivermectin"- generated 86
68 articles on PubMed, 48 on medRxiv and 37 on clinicaltrials.gov at the time of writing. Twelve
69 of these were listed as completed clinical trials and of these, 8 were included as investigators
70 had released results. Positive mortality benefit, reduced time to clinical recovery, reduced
71 incidence of disease progression and decreased duration of hospital admission were
72 reported in patients across all stages of clinical severity.

73 Limitations: Due to the time-critical nature of the COVID-19 pandemic our review included
74 preprint data, which must be interpreted with caution while it awaits peer review.
75

INTRODUCTION- COVID-19

The health and economic impact of COVID-19 is unparalleled. There has been no threat in recent times of the magnitude of COVID-19 to human survival and economic stability, with over 1,190,000 deaths reported globally to date and baseline economic forecasts of a 5.2 % contraction in global GDP in 2020.^{1,2} The likelihood of death in an at-risk population is substantial, with an estimated infection fatality ratio ranging between 11.6% and 16.4% in men ≥ 80 years, and between 4.6% and 6.5% in women ≥ 80 years.³ There is no validated vaccine for COVID-19 and there is currently no approved drug therapy that when given early in the disease course reduces morbidity or mortality. Treatments must therefore be established to mitigate the current global crisis. Furthermore, in order for these to be delivered in an egalitarian fashion, these must be affordable with scalable manufacturing potential to allow for delivery of therapy to be equitable and widespread. Repurposing of the anti-parasitic drug ivermectin to treat COVID-19 has become a point of scientific investigation following a study in Australia, which demonstrated its efficacy against SARS-CoV-2 in vitro.⁴ As many countries around the world find themselves in the grips of progressively more ominous second and third epidemic waves, we present the current in vitro, in silico and in vivo data surrounding the potential role of ivermectin in treating COVID-19.

IVERMECTIN- AN OVERVIEW

Ivermectin is a broad spectrum anti-parasitic agent that was first semi-synthetically derived from a fermentation broth of the soil bacteria *Streptomyces avermitilis* in 1975 in Japan.^{5,6} It belongs to the avermectin family and is the most widely used anti-parasitic in this class of drugs.⁶ It is listed as an essential medication by WHO and has been called a “wonder drug”.⁷ In 2015, William Campbell and Satoshi Ōmura were awarded a joint Nobel Prize in Medicine for their discovery and development of ivermectin.

For over 35 years ivermectin has been successfully used to treat various parasitic infections in humans and animals. Hundreds of millions of courses of ivermectin are delivered every year through mass drug administration campaigns as well as on an individual basis for the eradication of helminthic and arthropodal infections. Ivermectin binds to glutamate gated chloride channels in invertebrate nerve and muscle cell membranes, resulting in membrane hyperpolarisation which then leads to paralysis and death. These chloride channels are specific to protostome invertebrate phyla.⁸ While they are closely related to mammalian glycine receptors, ivermectin has a low affinity for mammalian ligand-gated chloride channels. In addition, ivermectin does not readily cross an intact blood brain barrier.⁷ Mutations in the *ABCB1* transporter gene known to occur in some animal species have been reported in humans but are predicted to be rare and should be readily recognized clinically as acute central nervous system (CNS) toxicity.⁹ These signs and symptoms can include tremor, myoclonus, ataxia, drooling, bradypnoea, anorexia, somnolence, mydriasis, salivation and paralysis.

Ivermectin is currently licensed for oral and topical use in humans, and oral, topical and parenteral use in animals, with standard dosing used typically between 150-400 $\mu\text{g}/\text{kg}$.⁷ There are several case reports of ivermectin being successfully used subcutaneously to treat patients with disseminated strongyloidiasis who fail oral therapy.¹⁰

Ivermectin has a well characterized wide safety margin, with several phase 1 studies demonstrating its safety even at 5-10 times its usual dose of 150-200 $\mu\text{g}/\text{kg}$, although there is limited data in pregnancy.^{7,11-15} There are no absolute drug contraindications listed by the

126 manufacturer.¹⁶ There have been rare reports of increased INR when ivermectin has been
127 co-prescribed with warfarin.¹⁷

128

129 Side effects are usually mild and self-limited, and include headache, dizziness, skin irritation
130 and nausea.¹⁷ A cumulative incidence of one serious adverse event per million was found
131 over the first 11 years of mass global ivermectin (trade name, Mectizan) administration.¹⁸

132

133

134 **IVERMECTIN- ANTIVIRAL PROPERTIES**

135 In addition to its anti-helminthic effects, ivermectin has also been shown to have antiviral
136 activity in vitro against numerous RNA and DNA viruses, including simian virus 40,
137 pseudorabies virus, human Immune-deficiency virus, dengue virus, West Nile virus,
138 Venezuelan equine encephalitis, influenza virus and yellow fever virus.¹⁹⁻²⁵ This broad-
139 spectrum antiviral activity is thought to be a result of the fact that ivermectin inhibits viral
140 protein transport mediated through the host importin α/β heterodimer (IMP- α/β).²⁴ Viral
141 protein translocation into the host nucleus through IMP α/β is known to be a crucial aspect
142 of robust infection for many viruses.²⁶⁻²⁸

143

144 The virological efficacy of ivermectin against dengue infection has been demonstrated in a
145 phase III clinical trial using 400 $\mu\text{g}/\text{kg}$, although no clinical efficacy was demonstrated in this
146 study.²⁹ This may be due to timing and dosing regimen of ivermectin.

147

148 An in vitro study recently demonstrated that ivermectin is active against SARS-CoV2, with
149 concentrations of 5 μM resulting in a 99.8% reduction of cell-associated SARS-CoV-2 RNA in
150 48 hours.⁴ While these drug concentrations are unlikely to be achieved in humans through
151 currently approved oral dosing regimens, this does not discount the possibility of efficacy in
152 vivo for many reasons. First, viral loads typically deployed for in vitro transfection
153 experiments are very high and may not be representative of the clinical scenario. Second, a
154 simple monolayer of the African green monkey kidney cells (Vero-hSLAM cells) with virus
155 introduced in the supernatant does not replicate the complex/dynamic human tissue
156 structure. Third, Vero-hSLAM cells may not be representative of the human model of
157 infection as these cells are not respiratory cells and do not have ACE-2 receptors through
158 which SARS-CoV-2 mediates cell entry.³⁰ Fourth, viral replication efficiency may vary in
159 different cell types. Indeed, Vero-hSLAM cells is a cell line favoured specifically for viral
160 replication. Fifth, synergistic effects inherent in the immunomodulatory and anti-
161 inflammatory properties of ivermectin may also result in lower concentrations required to
162 treat COVID-19. Finally, concentration limitations may potentially be overcome through
163 novel routes of administration and dosing regimens.

164

165

166 **IVERMECTIN- ANTI-INFLAMMATORY AND IMMUNOMODULATORY PROPERTIES**

167 Ivermectin and avermectin have been demonstrated to have anti-inflammatory and
168 immunomodulatory actions in several in vitro and animal models, and is licensed for topical
169 use in humans for the treatment of inflammatory lesions in rosacea.³¹

170

171 A recent proteomic analysis showed that ivermectin decreases levels of proteins associated
172 with SARS-CoV-2 in an in vitro culture system.³² An in vitro model of lipopolysaccharide (LPS)
173 induced inflammation demonstrated that avermectin, from which ivermectin is derived,
174 significantly impairs pro-inflammatory cytokine secretion (interleukin-1 β and tumour
175 necrosis factor- α) by 30% and doubles secretion of the immunoregulatory cytokine
176 interleukin (IL)-10. This effect is thought to be mediated through inhibition of nuclear

translocation of nuclear transcription factor κ -B (NF- κ B), and phosphorylation of mitogen activated protein (MAP) kinases.³³ Mice treated with ivermectin demonstrated improved survival rates with a reduction in tumour necrosis factor- α and IL-1, IL-6 compared to controls following a lethal dose of LPS.³⁴ The dose used in this study was approximately equivalent to about 18 mg in humans.³⁵ In a mouse model of allergic asthma, bronchoalveolar lavage fluid in oral ivermectin treated mice (2 mg/kg) demonstrated a significantly reduced number of immune cells and production of pro-inflammatory cytokines and antibodies compared to controls.³⁶ A suppression of mucous secretion by goblet cells was also observed. Immunomodulatory and anti-inflammatory effects have also been observed in a murine model of atopic dermatitis, where ivermectin was shown to improve allergic skin inflammation.³⁷ Ivermectin was shown to directly inhibit antigen-specific and non-specific-CD4+ and CD8+ T cell proliferation and effector functions (IL-4, interferon- γ and granzyme B production), whilst having no effect on dendritic cell migration and maturation.

IVERMECTIN- IN SILICO MODELLING

In silico models have raised the possibility that ivermectin may have several mechanisms of action against COVID-19 in addition to the established inhibition of IMP α/β . It is possible that ivermectin may be able to prevent cell entry of SARS-CoV-2 through blockade of a high affinity docking site on the human angiotensin converting enzyme 2 (ACE-2) receptor that has been identified through two independent computational modelling studies.^{38,39} The positioning of this identified binding site could theoretically interfere with the SARS-CoV-2 spike glycoprotein binding, and thus reduce viral entry into cells. Using a novel computation method to analyse kinetically active residues, Perisic showed homology between the binding site of ivermectin with its known target in parasites (glycine receptor α 3) and proteins on the surface of SARS-CoV-2.⁴⁰ Furthermore, two computational biology and molecular docking studies identified ivermectin as a potentially effective inhibitor of the RNA-dependent RNA polymerase of SARS-CoV-2.^{41,42}

METHODS

We conducted a comprehensive review of PubMed, medRxiv, ClinicalTrials.gov, Global Coronavirus COVID-19 Clinical Trial Tracker, World Health Organization International Clinical Trials Registry Platform, EU Clinical Trials Register, ANZ clinical trials registry, and references from relevant articles. Search keywords were “COVID-19 (and synonyms) AND ivermectin”. SK conducted the systematic review and selected articles. Decision regarding inclusion was then verified by JD and KC. Studies were included if they had released results at the time of writing. Studies were excluded if they had not released results, or if they had been retracted. Studies were not excluded based on site of study, time of follow-up or comparator arm. Study participants were limited to PCR confirmed COVID-19 patients and close contacts (healthcare workers and household contacts) of PCR confirmed COVID-19 patients. The intervention was ivermectin as either a monotherapy or combination therapy for COVID-19 or prophylaxis for COVID-19, irrespective of dose and timing of administration. Outcome measures in the treatment trials included all-cause mortality and time to clinical recovery, in addition secondary measures that included time to viral clearance and disease progression. The primary outcome measure in the prophylaxis trials was development of symptoms consistent with COVID-19 and/or development of PCR confirmed COVID-19.

RESULTS

Our trials database search using the keywords “COVID-19” and synonyms AND “ivermectin” revealed 86 articles on PubMed, 48 on medRxiv and 37 on clinicaltrials.gov at the time of writing. Of these, 12 were completed clinical studies that examined the effect of ivermectin as a combination or single therapy for COVID-19 treatment and prophylaxis. Eight of these had released results at the time of writing this review and met inclusion criteria. Of these studies, four are randomised controlled trials, one is a prospective cohort study, one is a matched case control study, one is a retrospective analysis, and one is a pilot study. Five of these studies were disease treatment trials, and three were prophylaxis trials. We expand upon these published and preprint results below, which are summarised in Table 1 and Table 2.

DISCUSSION- DATA FROM CLINICAL STUDIES

A multicentre retrospective analysis, known as the ICON study, reported an overall mortality benefit ($p=0.03$) in moderate-severe COVID-19 patients ($n=173$) who were given at least one dose of oral ivermectin in addition to standard therapy, compared to matched controls ($n=107$).⁴³ Two hundred and eight consecutive COVID-19 patients recruited across four hospitals in Florida were included in the study undertaken between March 15 and May 11, and divided into a treatment arm and a control arm. Standard approved dosing of 200 µg/kg was used, administered either as a single dose or followed by a second dose on day 7 at the discretion of the physician. Thirteen of the 173 patients who received ivermectin were given a second dose. Most patients in both groups were also prescribed hydroxychloroquine, azithromycin or both, with a higher use of both drugs noted in the control group before the secondary matched analysis. A statistically significant association between reduced mortality and ivermectin use was observed ($p=0.03$). This was even more pronounced in the subset of severe patients, with a mortality of 80.7% in controls vs 38.8 in the ivermectin group ($p=0.001$). This association remained significant following multivariate analysis to adjust for comorbidities and differences between groups, and in a propensity score-matched cohort ($p=0.045$ for total group; $p=0.002$ in severe subset). The absolute risk reduction was 11.7%. These results compare with the observed absolute risk reduction of dexamethasone use in severe patients of 12.1% seen in the RECOVERY trial, which was pivotal in introducing corticosteroids as standard of care in severe and critical COVID-19 patients in many countries.^{44,45} Despite a significant difference in overall mortality, and mortality in severely unwell COVID-19 patients, the ICON study was not powered to detect a mortality difference in moderately unwell patients, nor a reduction in duration of hospital stay or the rate of successful extubation. As a retrospective analysis it is also limited by potential unmeasured confounding factors, however the ivermectin group tended to have a greater proportion of patients with known COVID-19 risk factors.

A reduced time to hospital discharge was demonstrated in a pilot prospective preprint study of 16 hospitalised COVID-19 patients administered one dose of 200 µg/kg ivermectin in addition to standard therapy, compared to 71 matched controls receiving standard therapy alone (7.62 ± 2.75 versus 13.22 ± 0.90 days, $p=0.00005$).⁴⁶ Standard therapy was defined as hydroxychloroquine and azithromycin in this study. A signal for reduced mortality was also observed in the ivermectin group, however the study was not powered to address this endpoint.

A preprint observational analysis in medRxiv has reported on the mortality benefit of ivermectin combination therapy, known as the IDEA protocol, in COVID-19 patients ($n=167$) when compared to overall COVID-19 mortality in the region across the same time period ($p=0.0475$).⁴⁷ The IDEA protocol consists of three permutations of an ivermectin

combination treatment regime based on severity of COVID-19 upon commencement. This includes incrementally increasing doses of ivermectin and either aspirin or enoxaparin depending on severity of illness, as well as dexamethasone for moderate-severe hospitalised patients. Ivermectin doses of 300 µg/kg, 450 µg/kg and 600 µg/kg were prescribed to mild (n=135), moderate (n=12) and severe (n=22) cases respectively on days 0 and 7. A total of 167 patients were included in this study, with an average age of 55.7 years. Primary outcomes were progression of disease and 30 day mortality. There was a 0% rate of symptom progression within 7 days of follow-up in the mild patient group (n=135). No patients in this subgroup required admission to hospital and all made a full recovery. In the moderate to severe group (n=32), only one patient died after both 30 days and 2 months of follow up. Aside from this patient, disease progression did not occur in any of the remaining 31 moderate-severe patients after commencement of the IDEA protocol, and all proceeded to recover. This is in contrast to the interim report from the World Health Organisation (WHO) SOLIDARITY trial, which failed to show a reduction in disease progression with remdesivir, lopinavir, interferon β1 or hydroxychloroquine.⁴⁸ The overall mortality reported with the IDEA protocol was 0.59%. This compares to an overall mortality in the region of approximately 2.1% (p=0.045). The mortality rate in moderate-severe patients (n=32) receiving the IDEA protocol was 3.1%, as compared to a mortality rate of 25% in patients admitted to the same hospital over the same period who did not receive the IDEA protocol (n=12). This study is limited by the absence of a concurrent control arm with a matched number of moderate to severe patients. The overall 28 day mortality in a large randomised placebo controlled trial of remdesivir for COVID-19 was reported as 11.4% in the remdesivir group, compared to 15.2% in the control group.⁴⁹ In the subset of moderate to severe patients (ordinal score 5-7 at baseline) randomised to receive remdesivir, 12.2% died by day 28. The classification of moderate to severe disease between the IDEA and Remdesivir trials was comparable according to the study methods.

Doxycycline is a broad-spectrum antimicrobial with anti-inflammatory activities that has recently been shown to inhibit SARS-CoV-2 cell entry and replication in vitro, leading to trials that examine the synergistic effects of doxycycline and ivermectin.^{50,51} There are now two randomised controlled trials comparing ivermectin and doxycycline combination therapy with standard therapy that have published results on medRxiv and ClinicalTrials.gov (NCT04523831).^{52,53} The largest of these included 363 mild to moderate COVID-19 patients and tested a treatment regimen of a single dose of 6-12 mg ivermectin on day 0, with a 5 day course of 100mg doxycycline twice daily (NCT04523831).⁵³ 183 of the participants were randomised to receive ivermectin combination therapy plus standard care, while the remaining 180 were randomised to receive standard care. Results published on ClinicalTrials.gov indicate a higher rate of early clinical improvement within 7 days in the treatment group (60.7%) compared to control group (44.4%) (p=0.03) in addition to a lower rate of clinical deterioration in the treatment group (8.7%) vs control (17.8%) (p=0.013). This was mirrored in improved rates of viral clearance in the treatment group, where 7.7% of the treatment group vs 20% of controls were still returning a positive SARS-CoV-2 PCR 12 day after initial diagnosis. A mortality signal was also demonstrated, with zero deaths in the treatment group, compared to 3 deaths in the control group (1.6%). This is in contrast to corticosteroids, which, when used early are associated with possible harm.^{44,45} We await final analysis of these results in both preprint and peer-reviewed publication.

A randomised control trial in medRxiv studied the effect of ivermectin and doxycycline combination therapy on severe and critical COVID-19 patients in addition to mild to moderate cases.⁵² Seventy patients were randomised to the treatment arm, which consisted of 2-3 days of 200 µg/kg of ivermectin and 100 mg doxycycline twice daily for 5-10 days, in

addition to standard therapy. Forty eight patients in the treatment group were classified as mild-moderate, 11 as severe and 11 critical. This compared to 48 mild-moderate patients in the control arm and 22 severe patients. No critically ill patients were randomised to the control arm due to ethical considerations. A mortality benefit was demonstrated in the severe subset of patients, with a mortality rate of 0% in the treatment group compared to 27.27% in the control group ($p=0.052$). No patients died in the mild-moderate subsets of either group. The mortality rate in the critical group was 18.2%, and although there was no direct comparator group in this trial, this was lower than the mortality rate of the severe control group. Published mortality rates in COVID-19 patients admitted to ICU range between approximately 25.7%- 59.5%.⁵⁴ The WHO SOLIDARITY trial, in which 11,266 adult patients with COVID-19 were randomised to one of 4 or local standard of care reported an mortality rate of 49% amongst critically patients who were already intubated at time of randomisation.⁴⁸ A reduced median time to recovery was also demonstrated in both mild-moderate (6.34 ± 2.4 days vs 13.66 ± 6.4 days) and severe groups (20.27 ± 7.8 vs 24.25 ± 9.5 days) compared to controls, although this only reached statistical significance in the mild-moderate group ($p<0.01$), possibly due to small sample size of the severe group. This translates to a reduced time to recovery of 7.32 days in the mild-moderate treatment group and 3.98 days in the severe treatment group. The overall median time to recovery in the treatment group was 10.61 ± 5.3 days vs 17.9 ± 6.8 days ($p<0.01$). Remdesivir has been reported to reduce median time to recovery by 5 days ($p<0.001$).⁵⁵ This has been conflicted by interim reports from the SOLIDARITY trial, which did not find a significant reduction in hospital admission.⁴⁸ Furthermore, the SOLIDARITY trial has reported no definite mortality benefit of remdesivir (RR=0.95, CI 0.81-1.11; 301 deaths in 2743 remdesivir group, 303 deaths in the 2708 control group), even following a subgroup analysis for severity of illness.

Preprint results indicating that ivermectin may have a role in COVID-19 prophylaxis have recently been released on ClinicalTrials.gov (NCT04425850, NCT04422561).⁵³ These are summarised in Table 2. The IVERCAR study enrolled 229 healthcare workers in Argentina and divided participants into two groups, with the treatment group receiving ivermectin buccal drops and carrageenan nasal spray in addition to personal protective equipment (PPE), and the control group using PPE alone (NCT04425850). After 28 days of follow-up, no participants in the treatment group ($n=131$) had tested positive to COVID-19 compared to 11 participants in the control group ($n=98$), ($p<0.0001$).

These results were mirrored in a randomised controlled trial in Egypt, in which 304 participants who had household contacts with confirmed COVID-19 were randomised to receive ivermectin (200-400 $\mu\text{g/kg}$ on day 1 and day 3) or placebo (NCT04422561). Within the 14-day follow-up period, 7.4% of the treatment group had developed symptoms consistent with COVID-19, compared to 58.4% of the placebo group. PCR results had not been released at the time of writing this review, however even a reduction in symptomatic COVID-19 carries important individual health implications. These studies are in contrast to less encouraging or conflicting results from HCQ prophylaxis studies.⁵⁶⁻⁵⁸

Consistent with other prophylaxis reports, a recently released preprint matched case control study on medRxiv that analysed various medications used experimentally as COVID-19 prophylaxis, reported a 73% reduction of COVID-19 in healthcare workers following two doses of ivermectin (OR, 0.27; 95% CI 0.15-0.51).⁵⁹ The ivermectin prophylaxis regimen used in this study consisted of two doses of 300 $\mu\text{g/kg}$ of ivermectin separated by 72 hours.

381 FUTURE DIRECTIONS

382 Evidence is mounting which suggests that ivermectin may be an important drug in the fight
 383 against COVID-19. In the midst of a global pandemic the importance of preprint studies has
 384 come to the fore; however, we still await the outcome of rigorous peer review. Attributing
 385 therapeutic benefit to ivermectin use alone will be challenging, as combination therapies
 386 were commonly deployed. Interestingly, the apparent benefits of ivermectin or ivermectin
 387 combination therapy against COVID-19 appear to potentially be relevant to all stages of
 388 illness, from prophylaxis to treatment of critically ill patients. This may be explained by the
 389 multi-pronged effects of ivermectin, which range from direct viral inhibition to
 390 immunomodulation to mitigation of cell access, as demonstrated by in vitro, in silico and
 391 animal studies. Further immunological work needs to be undertaken to determine the
 392 specific mechanism of action of ivermectin with respect to its anti-inflammatory effects in
 393 COVID-19. Ivermectin is widely available, inexpensive, easy to administer and has a wide
 394 safety margin. The potential benefits of ivermectin may be enhanced by non-parenteral drug
 395 delivery. Three studies have recently published safety data in animal models of inhaled and
 396 intranasal ivermectin, reporting that these routes are safe in their respective models.⁶⁰⁻⁶²
 397 Further research in dosing, routes of administration, synergistic therapies and drug
 398 interactions will help inform the safest and most efficacious approach.

399
 400

REFERENCES

1. World Health Organization Coronavirus disease 2019 (COVID-19) Weekly epidemiological update 24 August, 2020. 2020. <https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports> (accessed August 29 2020).
2. The World Bank. The Global Economic Outlook During the COVID-19 Pandemic: A Changed World. . 2020. <https://www.worldbank.org/en/news/feature/2020/06/08/the-global-economic-outlook-during-the-covid-19-pandemic-a-changed-world> (accessed August 31 2020).
3. Pastor-Barriuso R, Perez-Gomez B, Hernan MA, et al. SARS-CoV-2 infection fatality risk in a nationwide seroepidemiological study. *medRxiv* 2020: 2020.08.06.20169722.
4. Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. *Antiviral Res* 2020; **178**: 104787.
5. Campbell WC, Burg RW, Fisher MH, Dybas RA. The Discovery of Ivermectin and Other Avermectins. In: Magee PS, Kohn GK, Menn JJ, eds. Pesticide synthesis through rational approaches. Washington, DC: American Chemical Society; 1984: 5–20.
6. Fisher MH, Mrozik H. The chemistry and pharmacology of avermectins. *Annu Rev Pharmacol Toxicol* 1992; **32**: 537–53.
7. Crump A, Ōmura S. Ivermectin, 'wonder drug' from Japan: the human use perspective. *Proc Jpn Acad Ser B Phys Biol Sci* 2011; **87**(2): 13–28.
8. Wolstenholme AJ. Glutamate-gated chloride channels. *J Biol Chem* 2012; **287**(48): 40232–8.
9. Baudou E, Lespine A, Durrieu G, et al. Serious Ivermectin Toxicity and Human ABCB1 Nonsense Mutations. *N Engl J Med* 2020; **383**(8): 787–9.
10. Marty FM, Lowry CM, Rodriguez M, et al. Treatment of human disseminated strongyloidiasis with a parenteral veterinary formulation of ivermectin. *Clin Infect Dis* 2005; **41**(1): e5–8.
11. Geary TG. Ivermectin 20 years on: maturation of a wonder drug. *Trends Parasitol* 2005; **21**(11): 530–2.
12. Kircik LH, Del Rosso JQ, Layton AM, Schaubert J. Over 25 Years of Clinical Experience With Ivermectin: An Overview of Safety for an Increasing Number of Indications. *J Drugs Dermatol* 2016; **15**(3): 325–32.
13. Omura S. Ivermectin: 25 years and still going strong. *Int J Antimicrob Agents* 2008; **31**(2): 91–8.
14. Guzzo CA, Furtek CI, Porras AG, et al. Safety, tolerability, and pharmacokinetics of escalating high doses of ivermectin in healthy adult subjects. *J Clin Pharmacol* 2002; **42**(10): 1122–33.
15. Nicolas P, Maia MF, Bassat Q, et al. Safety of oral ivermectin during pregnancy: a systematic review and meta-analysis. *Lancet Glob Health* 2020; **8**(1): e92–e100.
16. Merck Sharp & Dohme BV. Stromectol (Ivermectin): Product Information. Netherlands: Merck, Sharp & Dohme Corp.; 2018.

- 447 17. Gilbert BW, Slechta J. A Case of Ivermectin-Induced Warfarin Toxicity: First
448 Published Report. *Hosp Pharm* 2018; **53**(6): 393–4.
- 449 18. Omura S, Crump A. Ivermectin: panacea for resource-poor communities?
450 *Trends Parasitol* 2014; **30**(9): 445–55.
- 451 19. Götz V, Magar L, Dornfeld D, et al. Influenza A viruses escape from MxA
452 restriction at the expense of efficient nuclear vRNP import. *Sci Rep* 2016; **6**: 23138.
- 453 20. Lundberg L, Pinkham C, Baer A, et al. Nuclear import and export inhibitors
454 alter capsid protein distribution in mammalian cells and reduce Venezuelan Equine
455 Encephalitis Virus replication. *Antiviral Res* 2013; **100**(3): 662–72.
- 456 21. Lv C, Liu W, Wang B, et al. Ivermectin inhibits DNA polymerase UL42 of
457 pseudorabies virus entrance into the nucleus and proliferation of the virus in vitro
458 and vivo. *Antiviral Res* 2018; **159**: 55–62.
- 459 22. Mastrangelo E, Pezzullo M, De Burghgraeve T, et al. Ivermectin is a potent
460 inhibitor of flavivirus replication specifically targeting NS3 helicase activity: new
461 prospects for an old drug. *J Antimicrob Chemother* 2012; **67**(8): 1884–94.
- 462 23. Wagstaff KM, Sivakumaran H, Heaton SM, Harrich D, Jans DA. Ivermectin is a
463 specific inhibitor of importin α/β -mediated nuclear import able to inhibit replication
464 of HIV-1 and dengue virus. *Biochem J* 2012; **443**(3): 851–6.
- 465 24. Yang SNY, Atkinson SC, Wang C, et al. The broad spectrum antiviral
466 ivermectin targets the host nuclear transport importin α/β 1 heterodimer. *Antiviral
467 Res* 2020; **177**: 104760.
- 468 25. Heidary F, Gharebaghi R. Ivermectin: a systematic review from antiviral
469 effects to COVID-19 complementary regimen. *J Antibiot (Tokyo)* 2020; **73**(9): 593–
470 602.
- 471 26. Jans DA, Martin AJ, Wagstaff KM. Inhibitors of nuclear transport. *Curr Opin
472 Cell Biol* 2019; **58**: 50–60.
- 473 27. Fulcher AJ, Jans DA. Regulation of nucleocytoplasmic trafficking of viral
474 proteins: an integral role in pathogenesis? *Biochim Biophys Acta* 2011; **1813**(12):
475 2176–90.
- 476 28. Caly L, Wagstaff KM, Jans DA. Nuclear trafficking of proteins from RNA
477 viruses: Potential target for antivirals? *Antiviral Research* 2012; **95**(3): 202–6.
- 478 29. Yamasmit E, A-hamad Saleh-arong F, Avirutnan P, et al. Efficacy and Safety
479 of Ivermectin against Dengue Infection: A Phase III, Randomized, Double-blind,
480 Placebo-controlled Trial. The 34th Annual Meeting The Royal College of Physicians
481 of Thailand Pattaya, Chonburi, Thailand The Royal College of Physicians of Thailand;
482 2018.
- 483 30. Jans DA, Wagstaff KM. Ivermectin as a Broad-Spectrum Host-Directed
484 Antiviral: The Real Deal? *Cells* 2020; **9**(9).
- 485 31. Steinhoff M, Vocanson M, Voegel JJ, Hacini-Rachinel F, Schäfer G. Topical
486 Ivermectin 10 mg/g and Oral Doxycycline 40 mg Modified-Release: Current Evidence
487 on the Complementary Use of Anti-Inflammatory Rosacea Treatments. *Adv Ther*
488 2016; **33**(9): 1481–501.
- 489 32. Li N, Zhao L, Zhan X. Quantitative proteomics reveals a broad-spectrum
490 antiviral property of ivermectin, benefiting for COVID-19 treatment. *J Cell Physiol*
491 2020.

- 492 33. Ci X, Li H, Yu Q, et al. Ivermectin exerts anti-inflammatory effect by
493 downregulating the nuclear transcription factor kappa-B and mitogen-activated
494 protein kinase activation pathway. *Fundam Clin Pharmacol* 2009; **23**(4): 449–55.
- 495 34. Zhang X, Song Y, Ci X, et al. Ivermectin inhibits LPS-induced production of
496 inflammatory cytokines and improves LPS-induced survival in mice. *Inflamm Res*
497 2008; **57**(11): 524–9.
- 498 35. DiNicolantonio JJ, Barroso J, McCarty M. Ivermectin may be a clinically useful
499 anti-inflammatory agent for late-stage COVID-19. *Open Heart* 2020; **7**(2).
- 500 36. Yan S, Ci X, Chen N, et al. Anti-inflammatory effects of ivermectin in mouse
501 model of allergic asthma. *Inflamm Res* 2011; **60**(6): 589–96.
- 502 37. Ventre E, Rozières A, Lenief V, et al. Topical ivermectin improves allergic skin
503 inflammation. *Allergy* 2017; **72**(8): 1212–21.
- 504 38. Kalhor H, Sadeghi S, Abolhasani H, Kalhor R, Rahimi H. Repurposing of the
505 approved small molecule drugs in order to inhibit SARS-CoV-2 S protein and human
506 ACE2 interaction through virtual screening approaches. *J Biomol Struct Dyn* 2020: 1–
507 16.
- 508 39. Lehrer S, Rheinstein PH. Ivermectin Docks to the SARS-CoV-2 Spike
509 Receptor-binding Domain Attached to ACE2. *In Vivo* 2020; **34**(5): 3023–6.
- 510 40. Perišić O. Recognition of Potential COVID-19 Drug Treatments through the
511 Study of Existing Protein-Drug and Protein-Protein Structures: An Analysis of
512 Kinetically Active Residues. *Biomolecules* 2020; **10**(9).
- 513 41. Daghir Janabi AH. Effective Anti-SARS-CoV-2 RNA Dependent RNA
514 Polymerase Drugs Based on Docking Methods: The Case of Milbemycin, Ivermectin,
515 and Baloxavir Marboxil. *Avicenna J Med Biotechnol* 2020; **12**(4): 246–50.
- 516 42. Parvez MSA, Karim MA, Hasan M, et al. Prediction of potential inhibitors for
517 RNA-dependent RNA polymerase of SARS-CoV-2 using comprehensive drug
518 repurposing and molecular docking approach. *Int J Biol Macromol* 2020; **163**: 1787–
519 97.
- 520 43. Rajter JC, Sherman MS, Fatteh N, Vogel F, Sacks J, Rajter JJ. Use of Ivermectin
521 Is Associated With Lower Mortality in Hospitalized Patients With Coronavirus Disease
522 2019: The ICON Study. *Chest* 2020.
- 523 44. Horby P, Lim WS, Emberson JR, et al. Dexamethasone in Hospitalized Patients
524 with Covid-19 – Preliminary Report. *N Engl J Med* 2020.
- 525 45. Matthay MA, Thompson BT. Dexamethasone in hospitalised patients with
526 COVID-19: addressing uncertainties. *The Lancet Respiratory Medicine*.
- 527 46. Gorial FI, Mashhadani S, Sayaly HM, et al. Effectiveness of Ivermectin as add-
528 on Therapy in COVID-19 Management (Pilot Trial). *medRxiv* 2020:
529 2020.07.07.20145979.
- 530 47. Carvallo HE, Hirsch RR, Farinella ME. Safety and Efficacy of the combined use
531 of ivermectin, dexamethasone, enoxaparin and aspirin against COVID-19. *medRxiv*
532 2020: 2020.09.10.20191619.
- 533 48. Pan H, Peto R, Karim QA, et al. Repurposed antiviral drugs for COVID-19 –
534 interim WHO SOLIDARITY trial results. *medRxiv* 2020: 2020.10.15.20209817.
- 535 49. Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the Treatment of
536 Covid-19 — Final Report. *New England Journal of Medicine* 2020; **383**(19): 1813–26.
- 537 50. Gendrot M, Andreani J, Jardot P, et al. In Vitro Antiviral Activity of
538 Doxycycline against SARS-CoV-2. *Molecules* 2020; **25**(21).

539 51. Cazalis J, Bodet C, Gagnon G, Grenier D. Doxycycline reduces
540 lipopolysaccharide-induced inflammatory mediator secretion in macrophage and ex
541 vivo human whole blood models. *J Periodontol* 2008; **79**(9): 1762–8.

542 52. Hashim HA, Maulood MF, Rasheed AM, Fatak DF, Kabah KK, Abdulamir AS.
543 Controlled randomized clinical trial on using Ivermectin with Doxycycline for treating
544 COVID-19 patients in Baghdad, Iraq. *medRxiv* 2020: 2020.10.26.20219345.

545 53. ClinicalTrials.gov. Search Results for: ivermectin | Completed Studies |
546 Studies With Results | Covid19. 2020.
547 [https://clinicaltrials.gov/ct2/results?term=ivermectin&cond=Covid19&recrs=e&age](https://clinicaltrials.gov/ct2/results?term=ivermectin&cond=Covid19&recrs=e&agev=&gndr=&type=&rslt=With&Search=Apply)
548 [v=&gndr=&type=&rslt=With&Search=Apply](https://clinicaltrials.gov/ct2/results?term=ivermectin&cond=Covid19&recrs=e&agev=&gndr=&type=&rslt=With&Search=Apply) (accessed November 5 2020).

549 54. Quah P, Li A, Phua J. Mortality rates of patients with COVID-19 in the
550 intensive care unit: a systematic review of the emerging literature. *Crit Care* 2020;
551 **24**(1): 285.

552 55. Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the Treatment of
553 Covid-19 — Preliminary Report. *N Engl J Med* 2020.

554 56. Boulware DR, Pullen MF, Bangdiwala AS, et al. A Randomized Trial of
555 Hydroxychloroquine as Postexposure Prophylaxis for Covid-19. *N Engl J Med* 2020;
556 **383**(6): 517–25.

557 57. Bhattacharya R, Chowdhury S, Mukherjee R, et al. Pre exposure
558 hydroxychloroquine prophylaxis for covid-19 in healthcare workers: a retrospective
559 cohort. *medRxiv* 2020: 2020.06.09.20116806.

560 58. Rajasingham R, Bangdiwala AS, Nicol MR, et al. Hydroxychloroquine as pre-
561 exposure prophylaxis for COVID-19 in healthcare workers: a randomized trial.
562 *medRxiv* 2020: 2020.09.18.20197327.

563 59. Behera P, Patro BK, Singh AK, et al. Role of ivermectin in the prevention of
564 COVID-19 infection among healthcare workers in India: A matched case-control
565 study. *medRxiv* 2020: 2020.10.29.20222661.

566 60. Ji L, Cen J, Lin S, et al. Study on the subacute inhalation toxicity of ivermectin
567 in TC rats. *Chinese Journal of Comparative Medicine* 2016; **26**(3): 70–4.

568 61. Errecalde J, Lifschitz A, Vecchioli G, et al. Ivermectin repurposing for COVID-
569 19 therapy: Safety and pharmacokinetic assessment of a novel nasal spray
570 formulation in a pig model. *bioRxiv* 2020: 2020.10.23.352831.

571 62. Chaccour C, Abizanda G, Irigoyen-Barrio Á, et al. Nebulized ivermectin for
572 COVID-19 and other respiratory diseases, a proof of concept, dose-ranging study in
573 rats. *Scientific Reports* 2020; **10**(1): 17073.

574

575

576 **ACKNOWLEDGEMENTS**

577 Thank you to Dr. Salvatore Fiorenza for valuable discussions and assistance with manuscript
578 proof reading.

579

580

581 **CONFLICTS OF INTEREST**

582 The authors declare no relevant conflicts of interest.

Study reference	Study design	Study intervention	Total number of participants	Mortality rate (treatment group vs. comparator)	Disease progression or viral clearance (treatment group vs. comparator)	Duration of hospital admission or time to recovery (treatment group vs. comparator)
Rajter et al. 2020 ⁴²	Multicentre retrospective analysis	1-2 doses of 200 µg/kg IVM + standard therapy vs. standard therapy	280 hospitalised patients (IVM)= 173 (control)= 107	Overall study results 15% vs. 25.2% (p=0.03) Severe disease 38.8% vs. 80.7% (p=0.001)	No difference in successful rate of extubation	No significant difference
Gorial et al. 2020 ⁴⁵	Matched case-control	1 dose of 200 µg/kg IVM + standard therapy vs. standard therapy	87 hospitalised patients (IVM) = 16 (control)= 71	0% vs. 2.8% (p value not given)	Time to viral clearance: 7 days (95% CI 6-11) vs. 12 days (95% CI 10-15) (p<0.001)	7.62 ±2.75 vs. 13.22 ±0.90 days (p=0.00005)
Carvallo et al. 2020 ⁴⁶	Prospective single cohort study (simultaneous untreated controls)	IDEA protocol: Mild cases: IVM 300 µg/kg + aspirin Moderate cases: IVM 450 µg/kg + aspirin + dexamethasone Severe cases: 600 µg/kg IVM + enoxaparin + dexamethasone	167 mild-severe patients (mild) = 135 (moderate) = 12 (severe) = 22	Overall: 0.59% Mild cases: 0% Mod-severe cases: 3.1% Mortality of patients not on IDEA protocol at same hospital over duration of study: 25%	Disease progression: Mild cases: 0% 7 day symptom progression 0% required hospitalisation Moderate-severe cases: 1 patient (3.1%) had disease progression	Not reported

NCT04523831 ⁵⁰	Double blind randomised controlled trial	6-12 mg IVM + 5 days DOXY + standard therapy vs. standard therapy	363 mild - moderate (treatment) = 183 (control) = 180	0 % vs. 1.6% (p value not reported)	Clinical deterioration: 8.7% vs 17.8% (p=0.013) Viral clearance within 12 days: 92.3% vs. 80 % (p value not reported)	Clinical recovery within 7 days: 60.7% vs. 44.4% (p=0.03)
Hashim et al. 2020 ⁴⁹	Randomised controlled trial	2-3 days of 200 µg/kg IVM + 5-10 days DOXY + standard therapy vs. standard therapy	140 mild-critical patients (treatment) = 70 (48= mild-mod, 11= severe, 11= critical) (control) = 70 (48= mild-mod, 22=severe)	Mild=mod: 0% vs 0% Severe: 0% vs. 27.27 % (p=0.052)	Disease progression in severe cases: 9% vs. 31.81 % (p=0.15)	Time to recovery: 10.61±5.3 days vs. 17.9±6.8 days (p<0.01)

Table 1. Summary of key therapeutic ivermectin trials. (IVM ivermectin. DOXY doxycycline). Ivermectin was administered orally in all trials. “Standard therapy” differed between trials and is defined as the standard therapy administered in the region/hospital at the given period of the trial.

Study reference	Study design	Study intervention	Total number of participants	Incidence of COVID-19 infection (treatment vs. control)
NCT04425850 ⁵⁰	Prospective placebo controlled trial	1 drop IVM buccal drops (6mg/ml) + 5 sprays carrageenan nasal spray (0.17mg/spray) both repeated 5 times per day + PPE vs. PPE only	229 Healthcare workers (treatment) = 131 (control) = 98	0% vs. 11.22% Positive SARS-CoV2 PCR within 28 days (p<0.0001)
NCT04422561 ⁵⁰	Randomised controlled trial	IVM 200-400 µg/kg oral on day 1 and day 3 vs. no intervention	304 household contacts of confirmed COVID-19 case	7.4% vs. 58.4% symptomatic within 14 days (p value not reported)
Behera et al. 2020 ⁵⁶	Matched case-control study	Two doses IVM 300 µg/kg oral + PPE vs. PPE only	186 matched case-control pairs of Healthcare workers 77 controls took IVM 38 cases took IVM	IVM use associated with a 73% reduction. OR, 0.27 (95% CI 0.15-0.51)

Table 2. Summary of key COVID-19 prophylaxis ivermectin trials. (IVM ivermectin. PEE personal protective equipment)